The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Southwest District Health ended its COVID-19 vaccination program. Others in Texas, Florida and Michigan also pushed back ...

A new strain of norovirus is dominating the UK, with cases of the winter vomiting bug currently double the average for the ...

PHILADELPHIA — The same technology that saved millions of lives during the COVID-19 pandemic appears to hold promise against another scourge of infectious disease, according to new research from the ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...